The BCL2 inhibitor venetoclax (VEN), together with a hypomethylating agent or low-dose cytarabine, is the standard of care for older or unfit AML patients, and it is being evaluated as a “universal sensitizer” in many combinations in clinical trials (46). Here, BCL2 is linked to acute myeloid leukemia.